Apellis Pharmaceuticals, Inc.

NASDAQ:APLS

24.37 (USD) • At close March 13, 2025
Bedrijfsnaam Apellis Pharmaceuticals, Inc.
Symbool APLS
Munteenheid USD
Prijs 24.37
Beurswaarde 3,058,824,920
Dividendpercentage 0%
52-weken bereik 23.77 - 59.91
Industrie Biotechnology
Sector Healthcare
CEO Dr. Cedric Francois M.D., Ph.D.
Website https://www.apellis.com

An error occurred while fetching data.

Over Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA)

Vergelijkbare Aandelen

The Ensign Group, Inc. logo

The Ensign Group, Inc.

ENSG

125.47 USD

Medpace Holdings, Inc. logo

Medpace Holdings, Inc.

MEDP

317.93 USD

Tandem Diabetes Care, Inc. logo

Tandem Diabetes Care, Inc.

TNDM

18.18 USD

Lantheus Holdings, Inc. logo

Lantheus Holdings, Inc.

LNTH

99.29 USD

ICU Medical, Inc. logo

ICU Medical, Inc.

ICUI

140.19 USD

Premier, Inc. logo

Premier, Inc.

PINC

17.97 USD

QuidelOrtho Corporation logo

QuidelOrtho Corporation

QDEL

35.6 USD

Alkermes plc logo

Alkermes plc

ALKS

33.62 USD

CRISPR Therapeutics AG logo

CRISPR Therapeutics AG

CRSP

41.99 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)